• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ProQR Therapeutics N.V. - Ordinary Shares (NQ:PRQR)

1.680 -0.090 (-5.08%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ProQR Therapeutics N.V. - Ordinary Shares

< Previous 1 2 Next >
News headline image
ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook
January 08, 2026
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR to Participate in 8th Annual Evercore Healthcare Conference
December 01, 2025
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Third Quarter 2025 Operating and Financial Results
November 06, 2025
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025
October 20, 2025
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR to Participate in Upcoming Investor Conferences in October 2025
October 13, 2025
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Second Quarter 2025 Operating and Financial Results
August 07, 2025
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Upcoming Presentation at RNA Editing Summit
July 28, 2025
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
June 26, 2025
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences
May 12, 2025
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces First Quarter 2025 Operating and Financial Results
May 08, 2025
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference
May 02, 2025
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025
May 01, 2025
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
April 14, 2025
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Year End 2024 Operating and Financial Results
March 13, 2025
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration
December 11, 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist
December 10, 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024
December 05, 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Third Quarter 2024 Operating and Financial Results
November 07, 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
October 25, 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
October 22, 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
October 22, 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society
October 07, 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference
September 10, 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Second Quarter 2024 Operating and Financial Results
August 08, 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
June 18, 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces First Quarter 2024 Operating and Financial Results
May 09, 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
May 08, 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
April 23, 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
April 22, 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
April 19, 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap